Expedition Therapeutics secures $115M Series B as its COPD candidate launches Phase 2 trial

Expedition Therapeutics focuses on developing novel therapies for respiratory diseases, aiming to address unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD). The company announced a $115 million Series B financing round, with General Atlantic acting as the lead investor. The infusion of capital arrives as EXPD‑101, Expedition’s lead candidate, entered a Phase 2 clinical trial enrolling 600 patients diagnosed with COPD. While the announcement does not detail a specific use‑of‑funds plan, the timing suggests the new money will support the execution of the Phase 2 study, including patient recruitment, site management, and data collection. COPD remains a significant health challenge, representing a large market for innovative treatments, and Expedition’s advancement of a late‑stage candidate positions it among firms seeking to capture a share of this therapeutic area. By securing substantial backing from a prominent growth‑equity firm, Expedition signals confidence from investors in its scientific approach and the potential of EXPD‑101 to meet clinical endpoints that could pave the way for later‑stage development and eventual market entry. The Series B round underscores the company’s progression from early research toward larger, patient‑focused trials, marking a critical step in its roadmap toward delivering a new option for COPD patients.